[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"continuous-renal-replacement-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:continuous-renal-replacement-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100544452","continuous-veno-venous-hemodialysis-and-continuous-veno-venous-hemodiafiltration-on-urea-reduction-rate-in-intensive-care-patient-100544452",false,"NCT06369064","Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient","Comparison of the Effectiveness of Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patients With Acute Renal Injury : a Monocentric Controled Randomized Non Inferiority Open Labeled Study","CompEER","Inclusion criteria:\n\n* Adult patients hospitalized in ICU\n* Undergo RRT session because of AKI stage 3\n* At least one among criteria: pH \\\u003C 7,20 \u002F Blood urea \\> 30mM \u002F Fluid overload uncontrolled by with PaCO₂ \\\u003C 35 mmHg or mixed acidosis with PaCO₂ \\\u003C 50 mmHg.\n\n  * Oliguria lasting 72 hours or longer\n* Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization\n* Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation\n* Patient affiliated with Social Security.\n\nExclusion criteria:\n\n* End-stage chronic kidney disease on dialysis\n* Intoxication with a dialyzable toxin (lithium\n* Criteria for emergency dialysis initiation: hyperkaliemia \\>6,5mM with electrocardiographic signs\n* Medical contraindication to regional citrate: severe liver failure\n* Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding\n* Pregnant women, parturient or breast-feeding patient","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD).\n\nTo our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter).\n\nIn the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury.\n\nThe research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.",[27,28,29],"Acute Kidney Injury","Continuous Renal Replacement Therapy","Intensive Care Unit",[31,32,33],"continuous venovenous hemodiafiltration","continuous venovenous hemodialysis","urea reduction rate","RECRUITING","2026-05-15",{"date":37,"type":38},"2026-05-18","ACTUAL",{"date":40,"type":38},"2024-07-03",{"date":42,"type":21},"2028-08-15",{"name":44,"class":45},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100615540","post-filter-hematocrit-100615540","NCT07293936","Post-Filter Hematocrit","Validation of a Post-Filter Hematocrit Calculation Formula: A Comparative Analysis With Measured Post-Filter Hematocrit Values","CRRTHCT","Inclusion Criteria:\n\n* patients initiated on CRRT age equal than or greater to 18 years of age\n\nExclusion Criteria:\n\n* patients on ECMO",{"count":56,"type":21},20,[24],"Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the blood over the course of the filter. In convention, a cutoff of FF\\\u003C20-30% has been used to prevent hemofilter clotting, but no evidence correlating FF with hemofilter clotting has been documented. Some experts have proposed that post-filter hematocrit (Hct) could be a more direct marker for determining hemofilter clotting risk, but evidence supporting clinical utility of this marker is lacking.\n\nHCTpost=HCTpre\u002F(FF(HCTpre-1)+1)\n\nIn our proposed validation study, we hope to determine whether our formula for post-filter Hct provides accurate results when compared to measured values. The information obtained from this study will potentially justify the use of utilizing the formula in future studies.\n\nThe procedure of this study is collecting blood samples from the post-filter lines of patients on CRRT at different time points and different flow rates. This will be considered the \"measured post-filter hematocrit\" which will then be compared to the calculated formula above, using the other values obtained from daily labs (for pre-filter hematocrit) and CRRT machine settings.",[28,60,61],"Renal Failure","Hemofilter Clotting",[63,64,65,66,67],"crrt","continuous renal replacement therapy","hemofilter clotting","post-filter hematocrit","filtration fraction","2025-12-07",{"date":70,"type":38},"2025-12-19",{"date":72,"type":38},"2025-03-15",{"date":74,"type":21},"2026-03-15",{"name":76,"class":45},"Gwyndolyn M. Radford",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100517710","effects-of-different-continuous-renal-replacement-therapy-patterns-on-ionized-calcium-in-patients-with-citrate-anticoagulants-using-calcium-containing-replacement-solutions-100517710","NCT06021080","Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Receiving citrate anticoagulation;\n3. Obtain Informed consent from patients or next of kin.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Allergic to citrate anticoagulants;\n3. Severe liver dysfunction (total bilirubin levels exceeding two times the normal range);\n4. Hypoxemia (PaO2 \\\u003C 60 mmHg);\n5. Inadequate tissue perfusion (blood pressure \\\u003C 90\u002F60 mmHg despite high doses of vasoactive agents);\n6. Hyperlactatemia (lactate\\> 4 mmol\u002FL);\n7. Hypernatremia;\n8. Estimated length of hospital stay \\\u003C 48h;\n9. Participated in other studies.","100 Years",{"count":85,"type":21},30,"1 Month","OBSERVATIONAL","It is unclear whether different modes of continuous renal replacement therapy (CRRT) impact post-filter ionized calcium concentrations during regional citrate anticoagulation (RCA) when using calcium-containing replacement fluid.\n\nThis prospective, single-center, observational cohort study will screen all patients receiving CRRT for eligibility. General clinical information will be collected before commencing CRRT treatment. Patients will be randomly assigned to either the veno-venous hemofiltration (CVVH) or continuous veno-venous hemodialysis (CVVHD) group and switch to the alternative mode in the subsequent treatment session. Pre-filter and post-filter ionized calcium, systemic total and ionized calcium, and effluent total and ionized calcium will be measured 2 hours after the initiation of CRRT. Electrolyte levels, arterial blood gases, hourly citrate dose, and total citrate dose will be recorded every 6 hours until the end of CRRT. The primary outcome is the difference in ionized calcium concentrations at each site over time between the two modes.",[90,91,28],"Renal Injury","Regional Citrate Anticoagulation",[90,93,94],"Regional citrate anticoagulation","Continuous renal replacement therapy","2025-08-05",{"date":97,"type":38},"2025-08-06",{"date":99,"type":38},"2023-10-09",{"date":101,"type":21},"2026-12-09",{"name":103,"class":45},"Fujian Provincial Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100473845","filter-lifespan-in-continuous-renal-replacement-therapy-100473845","NCT05450185","Filter Lifespan in Continuous Renal Replacement Therapy","The Effect of Filter Lifespan in Continuous Renal Replacement Therapy on the Rate of New Infections in Critically Ill Patients: a Prospective, Multicenter, Observational Trial","CRRTInfO","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Critically ill patients with dialysis-dependent AKI\n* Continuous renal replacement therapy (CRRT)\n* Written informed consent\n\nExclusion Criteria:\n\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.73m2\n* Chronic dialysis dependency\n* Kidney transplant\n* (Glomerulo-)nephritis, interstitial nephritis, vasculitis\n* Patients on immunosuppression\n* Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis)\n* Persons with any kind of dependency on the investigator or employed by the sponsor or investigator",{"count":113,"type":21},600,"The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.",[116,28,117],"Critically Ill","Infections","2024-12-06",{"date":120,"type":38},"2024-12-12",{"date":122,"type":38},"2023-03-02",{"date":124,"type":21},"2025-08",{"name":126,"class":45},"University Hospital Muenster",5]